Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Australia Trade Balance Swings to Surprise Deficit as Imports Outpace Exports in May 
Wall Street Ends Mixed as Weak Jobs Data Lowers Fed Rate Hike Bets, Chip Stocks Tumble 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Japan Signals Readiness to Act on Yen as Intervention Speculation Grows 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
China Services PMI Beats Forecasts as Strong Demand Supports June Growth 
Oil Prices Slip as Oversupply Concerns and U.S.-Iran Talks Shape Market Outlook 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Mary Daly Says AI Uncertainty Clouds Fed Rate Outlook Despite Restrictive Policy 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
Abbott Laboratories is settling the case involving its two units, Arriva Medical LLC and its parent company Alere Inc. The American medical devices and health care company headquartered in Illinois will be paying $160 million to resolve the said units’ kickbacks and false claims cases.
The settlement stemmed from the allegations that Arriva Medical and Alere Inc. submitted untruthful claims to Medicare, a government health plan, by offering kickbacks to diabetes patients. According to the U.S. Department of Justice, some of the things they offered include free glucose monitors.
Reuters reported that the settlement was done on Monday, Aug. 2. This will resolve claims that Arriva Medical and Alere violated the country’s False Claims Act from 2009 to 2016 by transferring Medicare funding from where it was needed.
The U.S. DOJ stated that Arriva gave away glucose monitors at no cost to persuade patients to place orders for more testing supplies. It was added that Arriva also typically waives co-payments. It was further alleged that the company has been systematically charging Medicare for glucose monitors that were handed out to ineligible patients, plus submitting claims for 211 patients who were already dead for at least two weeks.
Gregory Goodman, the whistleblower of the scheme, worked at Arriva call center in Tennessee, and he will be getting $28.5 million from the settlement. Then again, despite the settlement, it was reported that the defendants did not admit liability.
"Doing anything that defrauds the government or the Medicare program, it's fellow Americans who end up paying for it," Goodman said. "The decision to move forward was quite simple."
According to the Tennessean, the now-retired employee knew something was not right when he took a call center job at Arriva almost 10 years ago. Prior to his stint at the medical supply company, he has been an account executive for investment firms.
He had little experience in the healthcare industry, so when he noticed that something was off, he did some research. Goodman explained he thinks the way the firm was driving customer service reps to sell those glucometers and waive co-payments was not normal. With this week’s settlement, it was proven that Abbott’s unit really did something wrong.
